|Bid||26.18 x 800|
|Ask||30.25 x 900|
|Day's Range||28.66 - 30.34|
|52 Week Range||24.75 - 31.20|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Tricida, Inc. , a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-dosed polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease, today announced the closing of its initial public offering of 13,455,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase ...
Inc., after five biotech IPOs were completed the week before. With public investors eager to tap into biotech innovation, startups this year have streamed onto Nasdaq despite market volatility that would have slowed offerings previously. Biotech IPO investors are taking a portfolio approach not unlike that of venture capitalists, said Cooley attorney Div Gupta.